Wedbush restated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. Wedbush currently has a $8.00 price objective on the stock. A number of other analysts have also issued reports on ELEV. HC Wainwright reiterated a buy rating and set […]